

Title (en)

USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS

Title (de)

VERWENDUNG VON NEUROKININ-1-ANTAGONISTEN ZUR BEHANDLUNG VON CHRONISCHEM PRURITUS

Title (fr)

UTILISATION D'ANTAGONISTES DE NEUROKININ-1 À DES FINS DE TRAITEMENT DU PRURIT CHRONIQUE

Publication

**EP 3829572 A1 20210609 (EN)**

Application

**EP 19840295 A 20190726**

Priority

- US 201862711123 P 20180727
- US 201862779285 P 20181213
- US 201962821126 P 20190320
- US 2019043710 W 20190726

Abstract (en)

[origin: WO2020023898A1] The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating chronic pruritus with a duration of at least about 6 months or 1 year. In some embodiments, the chronic pruritus is characterized by sensitization or hypersensitization of central neuron or/and peripheral neurons. In further embodiments, the chronic pruritus is characterized by spontaneously occurring itch, alloknosis or hyperknosis, or any combination or all thereof. The chronic pruritus can be associated with any medical conditions or can have an unknown cause (idiopathic). One or more additional antipruritic agents can optionally be used in combination with an NK-1 antagonist to treat chronic pruritus.

IPC 8 full level

**A61K 31/403** (2006.01); **A61K 9/00** (2006.01); **A61K 9/06** (2006.01); **A61K 31/4035** (2006.01); **A61K 45/06** (2006.01); **A61K 47/10** (2017.01)

CPC (source: EP)

**A61K 9/20** (2013.01); **A61K 31/4035** (2013.01); **A61K 45/06** (2013.01); **A61P 17/04** (2017.12)

Citation (search report)

See references of WO 2020023898A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2020023898 A1 20200130**; EP 3829572 A1 20210609

DOCDB simple family (application)

**US 2019043710 W 20190726**; EP 19840295 A 20190726